edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: AlzeCure Pharma
Edison Investment Research is terminating coverage on AlzeCure Pharma. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Previously published reports can still be accessed via our website.
AlzeCure Pharma — 2 videos in collection
AlzeCure Pharma is a clinical-stage biotech company based in Sweden focused on developing small molecule drugs for the treatment of Alzheimer’s disease (symptomatic and disease modifying) and pain (neuropathic and osteoarthritic).
• Tell us about the company and its key assets.
• Both Alzheimer’s disease and pain have been in the public spotlight recently. How has that affected your business?
• Please tell us about your pain assets.
• How large is the market for agents to deal with neuropathic pain?
• Please explain your TrkA-NAM project and its interest to large pharma.
• Do you see partnerships ahead?
• What is the current status of your two Alzheimer’s disease platforms and what are the next steps?
• What is the expected impact of the NeuroRestore asset on the patient?
• What is the expected impact of keeping Alzheimer’s patients out of full-time care for longer?
• Which milestones should investors look out for in the coming year?
Get access to the very latest content matched to your personal investment style.